{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T08:00:05Z","timestamp":1780992005563,"version":"3.54.1"},"reference-count":45,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100006293","name":"American Society of Clinical Oncology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006293","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.clml.2025.11.001","type":"journal-article","created":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T02:12:16Z","timestamp":1762308736000},"page":"123-127","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["SOHO State of the Art Updates and Next Questions | Richter Transformation in the Modern Era of Therapy"],"prefix":"10.1016","volume":"26","author":[{"given":"Isabella","family":"Marchal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Graham","family":"Wehmeyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam S.","family":"Kittai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"7","key":"10.1016\/j.clml.2025.11.001_bib0001","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1038\/s41375-022-01620-2","article-title":"The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: lymphoid Neoplasms","volume":"36","author":"Alaggio","year":"2022","journal-title":"Leukemia"},{"issue":"3","key":"10.1016\/j.clml.2025.11.001_bib0002","doi-asserted-by":"crossref","first-page":"765","DOI":"10.3324\/haematol.2019.224121","article-title":"Clinical characteristics and outcomes of Richter transformation: experience of 204 patients from a single center","volume":"105","author":"Wang","year":"2020","journal-title":"Haematologica"},{"issue":"10","key":"10.1016\/j.clml.2025.11.001_bib0003","doi-asserted-by":"crossref","first-page":"2513","DOI":"10.1007\/s00277-021-04603-y","article-title":"Outcomes of Richter's transformation of chronic lymphocytic leukemia\/small lymphocytic lymphoma (CLL\/SLL): an analysis of the SEER database","volume":"100","author":"Elnair","year":"2021","journal-title":"Ann Hematol"},{"issue":"6","key":"10.1016\/j.clml.2025.11.001_bib0004","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1111\/bjh.12458","article-title":"Diffuse large B-cell lymphoma (Richter syndrome) in patients with chronic lymphocytic leukaemia (CLL): a cohort study of newly diagnosed patients","volume":"162","author":"Parikh","year":"2013","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2025.11.001_bib0005","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.canep.2019.04.002","article-title":"Richter syndrome epidemiology in a large population based chronic lymphocytic leukemia cohort from Norway","volume":"60","author":"Lenartova","year":"2019","journal-title":"Can Epidemiol"},{"issue":"1","key":"10.1016\/j.clml.2025.11.001_bib0006","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1038\/s41375-020-0797-x","article-title":"Richter transformation in chronic lymphocytic leukemia (CLL)-a pooled analysis of German CLL Study Group (GCLLSG) front line treatment trials","volume":"35","author":"Al-Sawaf","year":"2021","journal-title":"Leukemia"},{"issue":"2","key":"10.1016\/j.clml.2025.11.001_bib0007","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1038\/s41375-024-02492-4","article-title":"Incidence of Richter transformation of chronic lymphocytic leukemia\/small lymphocytic lymphoma in the targeted therapy era","volume":"39","author":"Hampel","year":"2025","journal-title":"Leukemia"},{"issue":"7","key":"10.1016\/j.clml.2025.11.001_bib0008","doi-asserted-by":"crossref","first-page":"1564","DOI":"10.1038\/leu.2012.13","article-title":"Quantification of subclonal distributions of recurrent genomic aberrations in paired pre-treatment and relapse samples from patients with B-cell chronic lymphocytic leukemia","volume":"26","author":"Knight","year":"2012","journal-title":"Leukemia"},{"issue":"4","key":"10.1016\/j.clml.2025.11.001_bib0009","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1016\/j.cell.2013.01.019","article-title":"Evolution and impact of subclonal mutations in chronic lymphocytic leukemia","volume":"152","author":"Landau","year":"2013","journal-title":"Cell"},{"issue":"25","key":"10.1016\/j.clml.2025.11.001_bib0010","doi-asserted-by":"crossref","first-page":"3362","DOI":"10.1182\/blood-2017-01-763003","article-title":"Clinicopathological features and outcomes of progression of CLL on the BCL2 inhibitor venetoclax","volume":"129","author":"Anderson","year":"2017","journal-title":"Blood"},{"issue":"25","key":"10.1016\/j.clml.2025.11.001_bib0011","doi-asserted-by":"crossref","first-page":"2425","DOI":"10.1056\/NEJMoa1509388","article-title":"Ibrutinib as initial therapy for patients with chronic lymphocytic leukemia","volume":"373","author":"Burger","year":"2015","journal-title":"N Engl J Med"},{"issue":"23","key":"10.1016\/j.clml.2025.11.001_bib0012","doi-asserted-by":"crossref","first-page":"2225","DOI":"10.1056\/NEJMoa1815281","article-title":"Venetoclax and Obinutuzumab in patients with CLL and coexisting conditions","volume":"380","author":"Fischer","year":"2019","journal-title":"N Engl J Med"},{"issue":"24","key":"10.1016\/j.clml.2025.11.001_bib0013","doi-asserted-by":"crossref","first-page":"3327","DOI":"10.1182\/blood.2020009617","article-title":"Acalabrutinib in treatment-naive chronic lymphocytic leukemia","volume":"137","author":"Byrd","year":"2021","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.clml.2025.11.001_bib0014","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1016\/S1470-2045(22)00293-5","article-title":"Zanubrutinib versus bendamustine and rituximab in untreated chronic lymphocytic leukaemia and small lymphocytic lymphoma (SEQUOIA): a randomised, controlled, phase 3 trial","volume":"23","author":"Tam","year":"2022","journal-title":"Lancet Oncol"},{"issue":"15","key":"10.1016\/j.clml.2025.11.001_bib0015","doi-asserted-by":"crossref","first-page":"2343","DOI":"10.1200\/JCO.2005.05.0187","article-title":"Clinical outcomes and prognostic factors in patients with Richter's syndrome treated with chemotherapy or chemoimmunotherapy with or without stem-cell transplantation","volume":"24","author":"Tsimberidou","year":"2006","journal-title":"J Clin Oncol: Off J Am Societ Clin Oncol"},{"issue":"6","key":"10.1016\/j.clml.2025.11.001_bib0016","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1111\/bjh.16748","article-title":"Clinical outcome and prognostic factors of patients with Richter syndrome: real-world study of the Spanish Chronic Lymphocytic Leukemia Study Group (GELLC)","volume":"190","author":"Abrisqueta","year":"2020","journal-title":"Br J Haematol"},{"issue":"2","key":"10.1016\/j.clml.2025.11.001_bib0017","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1097\/RLU.0000000000002879","article-title":"Prognostic value of baseline total metabolic tumor volume measured on FDG PET in patients with Richter syndrome","volume":"45","author":"Pontoizeau","year":"2020","journal-title":"Clin Nuclear Med"},{"issue":"9","key":"10.1016\/j.clml.2025.11.001_bib0018","doi-asserted-by":"crossref","first-page":"E311","DOI":"10.1002\/ajh.26239","article-title":"Clinical, biological, and molecular genetic features of Richter syndrome and prognostic significance: a study of the French Innovative Leukemia Organization","volume":"96","author":"Moulin","year":"2021","journal-title":"Am J Hematol"},{"issue":"1","key":"10.1016\/j.clml.2025.11.001_bib0019","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1002\/ajh.26755","article-title":"Patient characteristics that predict Richter's transformation in patients with chronic lymphocytic leukemia treated with ibrutinib","volume":"98","author":"Kittai","year":"2023","journal-title":"Am J Hematol"},{"issue":"6","key":"10.1016\/j.clml.2025.11.001_bib0020","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1080\/10428194.2020.1719092","article-title":"Richter\u2019s transformation in patients with chronic lymphocytic leukaemia: a Nationwide epidemiological study","volume":"61","author":"Ben-Dali","year":"2020","journal-title":"Leuk Lymph"},{"issue":"1","key":"10.1016\/j.clml.2025.11.001_bib0021","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1038\/s41408-025-01236-6","article-title":"Outcomes of patients with Richter transformation who received no prior chemoimmunotherapy for their CLL","volume":"15","author":"Kittai","year":"2025","journal-title":"Blood Can J"},{"issue":"9","key":"10.1016\/j.clml.2025.11.001_bib0022","doi-asserted-by":"crossref","first-page":"1709","DOI":"10.1002\/ajh.27760","article-title":"Prognostic implication of karyotypic evaluation in patients with richter transformation in the modern era","volume":"100","author":"Miller","year":"2025","journal-title":"Am J Hematol"},{"issue":"3","key":"10.1016\/j.clml.2025.11.001_bib0023","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1182\/blood.2024028064","article-title":"International consensus statement on diagnosis, evaluation, and research of Richter transformation: the ERIC recommendations","volume":"146","author":"Kittai","year":"2025","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.clml.2025.11.001_bib0024","doi-asserted-by":"crossref","first-page":"1961","DOI":"10.1038\/s41375-022-01604-2","article-title":"Immunoglobulin gene sequence analysis in chronic lymphocytic leukemia: the 2022 update of the recommendations by ERIC, the European Research Initiative on CLL","volume":"36","author":"Agathangelidis","year":"2022","journal-title":"Leukemia"},{"issue":"3","key":"10.1016\/j.clml.2025.11.001_bib0025","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1038\/s41375-024-02163-4","article-title":"Updates of the ERIC recommendations on how to report the results from immunoglobulin heavy variable gene analysis in chronic lymphocytic leukemia","volume":"38","author":"Chatzikonstantinou","year":"2024","journal-title":"Leukemia"},{"issue":"11","key":"10.1016\/j.clml.2025.11.001_bib0026","doi-asserted-by":"crossref","first-page":"2773","DOI":"10.1182\/bloodadvances.2024015594","article-title":"Clonal relatedness as a prognostic marker in Richter transformation of chronic lymphocytic leukemia: a systematic review","volume":"9","author":"Barrett","year":"2025","journal-title":"Blood Adv"},{"issue":"2","key":"10.1016\/j.clml.2025.11.001_bib0027","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1111\/bjh.15035","article-title":"A single-institution retrospective cohort study of first-line R-EPOCH chemoimmunotherapy for Richter syndrome demonstrating complex chronic lymphocytic leukaemia karyotype as an adverse prognostic factor","volume":"180","author":"Rogers","year":"2018","journal-title":"Br J Haematol"},{"issue":"5","key":"10.1016\/j.clml.2025.11.001_bib0028","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1182\/blood.2021011386","article-title":"Venetoclax plus dose-adjusted R-EPOCH for Richter syndrome","volume":"139","author":"Davids","year":"2022","journal-title":"Blood"},{"issue":"S2","key":"10.1016\/j.clml.2025.11.001_bib0029","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1002\/hon.3164_343","article-title":"Initial results of a multicenter phase 2 study of venetoclax in combination with R-CHOP (VR-CHOP) for patients with Richter Syndrome","volume":"41","author":"Davids","year":"2023","journal-title":"Hematolog Oncol"},{"issue":"10","key":"10.1016\/j.clml.2025.11.001_bib0030","doi-asserted-by":"crossref","first-page":"2342","DOI":"10.1182\/bloodadvances.2023012080","article-title":"A multicenter study of venetoclax-based treatment for patients with Richter transformation of chronic lymphocytic leukemia","volume":"8","author":"Hampel","year":"2024","journal-title":"Blood Adv"},{"issue":"Supplement 1","key":"10.1016\/j.clml.2025.11.001_bib0031","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1182\/blood-2023-181108","article-title":"Pirtobrutinib in richter transformation: updated efficacy and safety results with 18-month median survival follow-up from the phase 1\/2 BRUIN study","volume":"142","author":"Wierda","year":"2023","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.clml.2025.11.001_bib0032","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1158\/2159-8290.CD-23-0670","article-title":"First-in-Human study of the reversible BTK inhibitor Nemtabrutinib in patients with relapsed\/refractory chronic lymphocytic leukemia and B-cell non\u2013Hodgkin lymphoma","volume":"14","author":"Woyach","year":"2024","journal-title":"Can Discover"},{"issue":"7","key":"10.1016\/j.clml.2025.11.001_bib0033","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1097\/PAS.0000000000001077","article-title":"PD-1 expression in chronic lymphocytic leukemia\/small lymphocytic lymphoma (CLL\/SLL) and large B-cell richter transformation (DLBCL-RT): a characteristic feature of DLBCL-RT and potential surrogate marker for clonal relatedness","volume":"42","author":"He","year":"2018","journal-title":"Am J Surg Pathol"},{"issue":"8","key":"10.1016\/j.clml.2025.11.001_bib0034","doi-asserted-by":"crossref","first-page":"3052","DOI":"10.1172\/JCI89756","article-title":"Ibrutinib treatment improves T cell number and function in CLL patients","volume":"127","author":"Long","year":"2017","journal-title":"J Clin Invest"},{"issue":"10","key":"10.1016\/j.clml.2025.11.001_bib0035","doi-asserted-by":"crossref","first-page":"1958","DOI":"10.1182\/bloodadvances.2022008790","article-title":"A phase 2 study of nivolumab combined with ibrutinib in patients with diffuse large B-cell richter transformation of CLL","volume":"7","author":"Jain","year":"2023","journal-title":"Blood Adv"},{"issue":"16_suppl","key":"10.1016\/j.clml.2025.11.001_bib0036","doi-asserted-by":"crossref","first-page":"7050","DOI":"10.1200\/JCO.2024.42.16_suppl.7050","article-title":"Efficacy of pembrolizumab monotherapy and in combination with BCR inhibitors for Richter transformation of chronic lymphocytic leukemia (CLL)","volume":"42","author":"Wang","year":"2024","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.clml.2025.11.001_bib0037","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1038\/s41591-023-02722-9","article-title":"Tislelizumab plus zanubrutinib for Richter transformation: the phase 2 RT1 trial","volume":"30","author":"Al-Sawaf","year":"2024","journal-title":"Nat Med"},{"key":"10.1016\/j.clml.2025.11.001_bib0038","unstructured":"Network NCC. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae): CLL V3. 2025. https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/cll.pdf. Accessed August 20, 2025."},{"key":"10.1016\/j.clml.2025.11.001_bib0039","doi-asserted-by":"crossref","DOI":"10.3324\/haematol.2024.286945","article-title":"Safety and efficacy of the combination of copanlisib and nivolumab in patients with Richter's transformation or transformed non-hodgkin lymphoma: results from a phase I trial","author":"Shouse","year":"2025","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2025.11.001_bib0040","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.1182\/blood-2021-154279","article-title":"Venetoclax, Obinutuzumab and Atezolizumab (PD-L1 Checkpoint Inhibitor) for treatment for patients with richter transformation","volume":"138","author":"Jain","year":"2021","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.clml.2025.11.001_bib0041","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1016\/S1470-2045(24)00396-6","article-title":"Atezolizumab, venetoclax, and Obinutuzumab combination in Richter transformation diffuse large B-cell lymphoma (MOLTO): a multicentre, single-arm, phase 2 trial","volume":"25","author":"Tedeschi","year":"2024","journal-title":"Lancet Oncol"},{"issue":"17","key":"10.1016\/j.clml.2025.11.001_bib0042","doi-asserted-by":"crossref","first-page":"2071","DOI":"10.1200\/JCO.24.00033","article-title":"Anti-CD19 chimeric antigen receptor T-cell therapy for richter transformation: an international, multicenter, retrospective study","volume":"42","author":"Kittai","year":"2024","journal-title":"J Clin Oncol: Off J Am Society Clin Oncol"},{"issue":"11","key":"10.1016\/j.clml.2025.11.001_bib0043","first-page":"3566","article-title":"Anti-CD19 chimeric antigen receptor T-cell therapy has less efficacy in Richter transformation than in de novo large B-cell lymphoma and transformed low-grade B-cell lymphoma","volume":"109","author":"Benjamini","year":"2024","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2025.11.001_bib0044","doi-asserted-by":"crossref","DOI":"10.1111\/bjh.20236","article-title":"Anti-CD19 CAR T-cell therapy for patients with Richter transformation: a LYSA study from the DESCAR-T registry","author":"Bensaber","year":"2025","journal-title":"Br J Haematol"},{"issue":"18","key":"10.1016\/j.clml.2025.11.001_bib0045","doi-asserted-by":"crossref","first-page":"3528","DOI":"10.1182\/bloodadvances.2021004865","article-title":"Autologous and allogeneic hematopoietic cell transplantation for diffuse large B-cell lymphoma-type Richter syndrome","volume":"5","author":"Herrera","year":"2021","journal-title":"Blood Adv"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265025042715?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265025042715?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T07:41:32Z","timestamp":1780990892000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265025042715"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":45,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["S2152265025042715"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2025.11.001","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"SOHO State of the Art Updates and Next Questions | Richter Transformation in the Modern Era of Therapy","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2025.11.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}